(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.Date of event: date of occurrence has been estimated.Udi #: the udi (unique device identifier) is unknown because the part number was not provided.The device was not returned for evaluation.A review of the electronic lot history record (elhr) was not performed since the part and lot number were not reported and the product and packaging were not returned for analysis.The reported patient effects of ischemia and thrombosis are listed in the electronic instructions for use supera peripheral stent systems as known patient effects of the stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the procedure was to treat a non-tortuous, moderately calcified mid superficial femoral artery (sfa) with restenosed at 70%.The patient has been in cancer remission and arrived with thrombosis in the left femoral artery.Initially, thrombectomy was performed and then a second intervention was required to treat the restenosed sfa.An unspecified supera stent was implanted.A month later the patient was re-hospitalized due to intra-stent thrombosis of the supera.The physician had to amputate the left leg due to irreversible ischemia.Per the physician, the thrombosis was due to cancer metastasis which has now presented in the lungs; she states that the supera device and event are not related.No additional information was provided.
|